Baudax Drug Patent Portfolio

Baudax owns 1 orange book drug protected by 8 US patents Given below is the list of Baudax's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10881663 Method of treating pain in elderly patients with mild renal impairment 08 Mar, 2039
Active
US11458145 Methods of administering intravenous meloxicam in a bolus dose 08 Mar, 2039
Active
US10709713 Nanoparticulate meloxicam formulations 26 May, 2030
Active
US11253478 Reduction of flake-like aggregation in nanoparticulate active agent compositions 26 May, 2030
Active
US9974746 Reduction of flake-like aggregation in nanoparticulate active agent compositions 26 May, 2030
Active
US10463673 Nanoparticulate meloxicam formulations 24 Feb, 2024 Expired
US10471067 Nanoparticulate meloxicam formulations 24 Feb, 2024 Expired
US8512727 Nanoparticulate meloxicam formulations 25 Dec, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Baudax.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 05 Jul, 2024 US10881663
Payment of Maintenance Fee, 4th Year, Large Entity 15 Jan, 2024 US10709713
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 06 Nov, 2023 US10709713
Surcharge for Late Payment, Large Entity 22 Aug, 2023 US10463673 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 22 Aug, 2023 US10463673 (Litigated)
Electronic Review 28 Jun, 2023 US10709713
Change in Power of Attorney (May Include Associate POA) 28 Jun, 2023 US10463673 (Litigated)
Electronic Review 28 Jun, 2023 US10471067 (Litigated)
Email Notification 28 Jun, 2023 US10471067 (Litigated)
Email Notification 28 Jun, 2023 US10709713
Change in Power of Attorney (May Include Associate POA) 28 Jun, 2023 US10709713
Change in Power of Attorney (May Include Associate POA) 28 Jun, 2023 US10471067 (Litigated)
Email Notification 28 Jun, 2023 US10463673 (Litigated)
Electronic Review 28 Jun, 2023 US10463673 (Litigated)
Change in Power of Attorney (May Include Associate POA) 27 Jun, 2023 US10881663


Baudax's Family Patents

Baudax drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 42.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Baudax Drug List

Given below is the complete list of Baudax's drugs and the patents protecting them.


1. Anjeso

Anjeso is protected by 8 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10881663 Method of treating pain in elderly patients with mild renal impairment 08 Mar, 2039
(14 years from now)
Active
US11458145 Methods of administering intravenous meloxicam in a bolus dose 08 Mar, 2039
(14 years from now)
Active
US10709713 Nanoparticulate meloxicam formulations 26 May, 2030
(5 years from now)
Active
US11253478 Reduction of flake-like aggregation in nanoparticulate active agent compositions 26 May, 2030
(5 years from now)
Active
US9974746 Reduction of flake-like aggregation in nanoparticulate active agent compositions 26 May, 2030
(5 years from now)
Active
US10463673 Nanoparticulate meloxicam formulations 24 Feb, 2024
(7 months ago)
Expired
US10471067 Nanoparticulate meloxicam formulations 24 Feb, 2024
(7 months ago)
Expired
US8512727 Nanoparticulate meloxicam formulations 25 Dec, 2022
(1 year, 9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Anjeso's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List